Market Overview

Global Peptide Therapeutics Market size was valued at around 43.55 billion in 2023 and is expected to reach a value of USD 72.95 billion by 2032, at a CAGR of 5.9% over the forecast period (2024–2032).

The Forecast Period of Peptide Therapeutics Market:

In the coming years, it is expected that the increasing prevalence of cancer and metabolic disorders such as osteoporosis, obesity, and diabetes would enhance the application of peptide therapies. The need for affordable and effective drugs is triggered by the increasing number of paediatric patients with these diseases as well as the fact that they are prevalent in low-income regions.

The market will emerge because of increasing rates of different malignancies and an increased requirement for proper treatment options. For instance, the International Agency for Research on Cancer (IARC) has estimated that there will be more than 20.7 million new cancer cases in 2023. Early treatment of cancer with peptide therapies can promote disease control and reduce mortality. Over the forecast period, increasing demand for efficient and rapid-acting remedies is expected to fuel market growth. One out of six individuals, or 10 million deaths, will be due to cancer in 2020, rendering it a significant killer globally. Obesity, excessive body mass index, alcohol abuse, smoking, and elevated cholesterol are all connected with one-third of cancer-caused deaths.

With companies focusing on developing new drugs, the market will grow at a profitable CAGR during the forecast period. To develop cures for their target diseases and increase their market share, companies are significantly engaged in research and development (R&D). Peptide therapies R&D is predominantly concentrated on metabolic disease, followed by oncology and infectious diseases. Peptide therapy laws are evolving to incorporate more stringent standards for approval on the basis of efficacy, safety, and quality. To facilitate the clearance of peptide therapies at a faster rate, regulatory bodies such as the FDA and EMA are now considering new standards.

But purification of long peptides for chemical functionalisation and resin swelling is inhibited by the limited solid-phase reactor capacity. Synthesis has been more complex as a result of more modifications and inclusion of more unnatural amino acids. Certain peptides being developed are hard to separate and purify because of their length, three-dimensional conformational structures, and modified amino acid composition.

Key Findings:

Market Drivers

Advancements in Peptide Synthesis Technologies

• The global market for peptide drugs has grown significantly owing in great part to advances in peptide synthesis technology. Such technologies, which have enhanced peptide production to be more efficient, scalable, and economical, include solid-phase peptide synthesis (SPPS), recombinant DNA technology, and hybrid peptide synthesis technologies. As SPPS can control peptide chain assembly with high efficiency, with superb purity and yield guaranteed, it has emerged as a significant factor in the production of complex peptides. Similarly, improvements in recombinant DNA technology allow peptide drugs to be synthesized in mammalian or microbial cell cultures, providing a reliable and scalable approach to large-scale production.
• Improvements in peptide modification technologies such as PEGylation and cyclisation have significantly enhanced the stability, bioavailability, and therapeutic activity of peptides. The modifications enhance the half-life of peptide drugs and reduce their enzymic degradation, thus making them more convenient to use in treating acute and chronic diseases. The automation of peptide synthesis processes has also minimized time frames for drug discovery and development to enable new treatments to proceed with clinical trials earlier.

Market Opportunities

oral peptide therapeutic development

• Several technologies are in development to enable oral administration of peptides. While each has a specific combination of characteristics and abilities, all have to overcome formidable hurdles in order to deliver peptides orally successfully. To begin with, the oral dosage form has to withstand the stomach's extremely acidic pH. Following stomach passage, the design of the tablet should enable breakdown in the increased pH environment of the small intestine while protecting the peptide payload from protease enzyme cleavage. Finally, there need to be mechanisms that enable the peptide to be taken up by the relatively impermeable intestinal epithelium.

Market Restraining Factors

The impact of new technologies

• It's worth noting why and what could have altered the bias against peptides as drug agents, because they were never the most favoured options for drugs. Peptide-based therapies were reserved to treat hormonal lesions and, in turn, hormone-dependent cancer for centuries. Currently, other indications were not quite evident. In addition, due to their chemical composition, peptides were expensive and difficult to manufacture as drugs. Also, they often had extremely short half-lives, making chronic administration costly and problematic. The main disadvantage, however, was the lack of oral availability.

Segmentation Analysis

The market scope is segmented because of by Type, by Type of Manufacturers, by Application.

By Type

Based on the Type of the market is segmented into Generic, Innovative.

Owing to increased R&D spending by dominant pharmaceutical companies to explore and establish new drugs, as well as prescription volumes, the innovative market dominated the business in 2023 with an over 61.69% revenue share. Innovative peptide drugs are driven by several significant industry drivers. Increased interest in peptide therapeutics as a hopeful therapy for sophisticated disorders is caused by its significant specificity and potential for individualized therapies. Reasons behind this lie in advances made in peptide synthesis, modification approaches, and delivering technologies, due to which there is a potential for developing novel and more efficacious peptide-derived drugs.

Over the forecast period, the generic segment is expected to grow at the highest rate. Within the pharmaceutical sector, generic peptide drugs are an emerging trend. Generic companies create bioequivalent versions when patents have lapsed on original peptide medications to increase access by patients and lower medical expenses. The overall trend for cheaper and reasonably priced health care is consistent with this trend. More than 70 peptide-based drugs are sold globally, for instance, and as their patents are set to run out, a number of prescription peptide drugs, such as Byetta and Victoza, could become generic.

By Type of Manufacturers

Based on the Type of Manufacturers of the market is segmented into In-house, Outsourced.

The production unit within-house made a contribution of approximately 64.8% to total revenue in the year 2023. Better quality control of the production, lower costs, and intellectual property protection are some of the reasons behind such a strategic move. Peptides play a significant role as they are very targeted and less toxic, and this is being driven by the growing demand for specific and targeted medication. Pharmaceutical companies are investing in developing their own peptide production capabilities to guarantee a stable supply chain and shorter development timelines. In-house production of peptide drugs is on the rise due to the demand for precision medicines and shorter development timelines. Pharmaceutical companies can leverage this strategic approach to stay competitive in a continually evolving therapeutic environment.

During the forecast period, the outsourcing manufacturing segment is anticipated to grow at the fastest CAGR. Peptide manufacturing is a complex process that requires advanced technologies such as Solid-Phase Peptide Synthesis (SPPS), Liquid-Phase Peptide Synthesis (LPPS), or Hybrid to purify and synthesise high-quality products. Due to this, the cost of manufacturing is high. In addition, it is estimated that expansion in the market will result from major players' rising capital investment and R&D expenditure through strategic partnerships. In addition, the market is unfolding promising prospects owing to strategic operations by major market players. For instance, CordenPharma, in July 2020, expanded its GMP API plant in Colorado to produce peptides.

Regional Snapshots

By region, Insights into the markets in North America, Europe, Asia-Pacific, Latin America and MEA are provided by the study. North America led the market in 2023 with a revenue share of more than 45.80% because of the release of successful products and well-established production bases throughout the continent. Furthermore, the growing occurrence of diseases like cancer, heart disease, lung disease, infectious disease, metabolic disease, and others is likely to propel market growth. There are approximately 1.9 million cases of new cancer being developed in the area each year, and it is the top cause of death in Canada and the second top cause of death in the United States after heart disease, according to the Cancer Atlas. Cardiovascular diseases, such as heart disease, stroke, heart failure, and high blood pressure, are among the leading causes of death in the United States.

As a result of various factors, including untapped potential, inexpensive raw materials, more outsourced service providers, the biotech industry, and growing R&D expenditure, the Asia Pacific region is likely to witness a huge surge in growth over the next few years. The sun setting on new medicine patents and the decline in raw materials prices are also considered to be factors contributing to the generic market's high compound annual growth rate. The region is expected to have several opportunities for growth through the combined effect of these factors.

List of Companies Profiled

• Eli Lilly and Company
• Pfizer Inc.
• Amgen Inc.
• Takeda Pharmaceutical Company Limited
• AstraZeneca
• Teva Pharmaceutical Industries Ltd.
• Sanofi
• Hoffmann-La Roche Ltd
• Novartis AG
• Novo Nordisk A/S
• GlaxoSmithKline plc.
• Ironwood Pharmaceuticals, Inc.
• Radius Health, Inc.
• Ipsen Pharma

Key Industry Developments

In October 2023, British synthetic peptide manufacturer Pepceuticals Limited was acquired by Biosynth with a view to strengthening its peptide operations.

In March 2023, PeptiDream and Ono Pharmaceuticals collaborated to study Macrocyclic Constrained Peptide Therapeutics and discover new medicines.

Report Coverage

The report will cover the qualitative and quantitative data on the Global Peptide Therapeutics Market. The qualitative data includes latest trends, market players analysis, market drivers, market opportunity, and many others. Also, the report quantitative data includes market size for every region, country, and segments according to your requirements. We can also provide customize report in every industry vertical.

Report Scope and Segmentations

Global Peptide Therapeutics Market Regional Analysis

North America accounted for the highest xx% market share in terms of revenue in the Peptide Therapeutics market and is expected to expand at a CAGR of xx% during the forecast period. This growth can be attributed to the growing adoption of Peptide Therapeutics. The market in APAC is expected to witness significant growth and is expected to register a CAGR of xx% over upcoming years, because of the presence of key Peptide Therapeutics companies in economies such as Japan and China.

The objective of the report is to present comprehensive analysis of Global Peptide Therapeutics Market including all the stakeholders of the industry. The past and current status of the industry with forecasted market size and trends are presented in the report with the analysis of complicated data in simple language.

Peptide Therapeutics Market Report is also available for below Regions and Country Please Ask for that

North America

• U.S
• Canada

Europe

• Switzerland
• Belgium
• Germany
• France
• U.K
• Italy
• Spain
• Sweden
• Netherland
• Turkey
• Rest of Europe

Asia-Pacific

• India
• Australia
• Philippines
• Singapore
• South Korea
• Japan
• China
• Malaysia
• Thailand
• Indonesia
• Rest Of APAC

Latin America

• Mexico
• Argentina
• Peru
• Colombia
• Brazil
• Rest of South America

Middle East and Africa

• Saudi Arabia
• UAE
• Egypt
• South Africa
• Rest Of MEA

Points Covered in the Report

• The points that are discussed within the report are the major market players that are involved in the market such as market players, raw material suppliers, equipment suppliers, end users, traders, distributors and etc.
• The complete profile of the companies is mentioned. And the capacity, production, price, revenue, cost, gross, gross margin, sales volume, sales revenue, consumption, growth rate, import, export, supply, future strategies, and the technological developments that they are making are also included within the report. This report analysed 5 years data history and forecast.
• The growth factors of the market are discussed in detail wherein the different end users of the market are explained in detail.
• Data and information by market player, by region, by type, by application and etc., and custom research can be added according to specific requirements.
• The report contains the SWOT analysis of the market. Finally, the report contains the conclusion part where the opinions of the industrial experts are included.

Key Questions

• How much the global Peptide Therapeutics Market valued?
• Which region has the largest share in 2024 for the global Peptide Therapeutics Market?
• What are the driving factors for the market?
• Which is the leading segment in the global market?
• What are the major players in the market?

Research Scope of Peptide Therapeutics Market

• Historic year: 2019- 2022
• Base year: 2023
• Forecast: 2024 to 2032
• Representation of Market revenue in USD Billion